LENZ Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 152

Employees

  • Stock Symbol
  • LENZ

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $3.33
  • (As of Thursday Closing)

LENZ Therapeutics General Information

Description

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

Contact Information

Website
www.lenz-tx.com
Formerly Known As
Presbyopia Therapies, Graphite Bio
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 201 Lomas Santa Fe Drive
  • Suite 300
  • Solana Beach, CA 92075
  • United States
+1 (888)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 201 Lomas Santa Fe Drive
  • Suite 300
  • Solana Beach, CA 92075
  • United States
+1 (888)

LENZ Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LENZ Therapeutics Stock Performance

As of 19-Nov-2026, LENZ Therapeutics’s stock price is $3.33. Its current market cap is $105M with 31.4M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.33 $3.20 $2.80 - $32.13 $105M 31.4M 885K -$4.49

LENZ Therapeutics Financials Summary

As of 30-Sep-2026, LENZ Therapeutics has a trailing 12-month revenue of $12.4M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (98,780) 299,422 578,422
Revenue 12,359 19,088 0 0
EBITDA (149,714) (91,094) (58,263) (72,321)
Net Income (140,271) (82,127) (49,769) (69,968)
Total Assets 209,749 305,876 215,304 70,376
Total Debt 460 815 1,381 329
Public Fundamental Data provided by Morningstar, Inc. disclaimer

LENZ Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore LENZ Therapeutics‘s full profile, request access.

Request a free trial

LENZ Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore LENZ Therapeutics‘s full profile, request access.

Request a free trial

LENZ Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to i
Drug Discovery
Solana Beach, CA
152 As of 2025

Durham, NC
 

Palo Alto, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

LENZ Therapeutics Competitors (8)

One of LENZ Therapeutics’s 8 competitors is Opus Genetics, a Formerly VC-backed company based in Durham, NC.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Opus Genetics Formerly VC-backed Durham, NC
Kodiak Sciences Formerly VC-backed Palo Alto, CA
Cloudbreak Pharma Formerly VC-backed Irvine, CA
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI
Foventa Therapeutics Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 5 of 8 competitors. Get the full list »

LENZ Therapeutics Patents

LENZ Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024249927-A1 Methods for clinical-scale production of genetically modified primary cells Inactive 01-Jun-2023
WO-2024137533-A1 Improved peptide inhibitors of p53 binding protein 53bp1 Inactive 19-Dec-2022
WO-2024097373-A1 Methods for genotyping gene-edited hematopoietic stem cells Inactive 02-Nov-2022
EP-4476344-A2 Adaptations for high efficiency i-f3-crispr-cas systems for guide rna-directed transposition in human cells Pending 09-Feb-2022
EP-4476344-A4 Adaptations for high efficiency i-f3-crispr-cas systems for guide rna-directed transposition in human cells Pending 09-Feb-2022 C07K14/195
To view LENZ Therapeutics’s complete patent history, request access »

LENZ Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

LENZ Therapeutics Acquisitions (1)

LENZ Therapeutics’s most recent deal was a Merger/Acquisition with Graphite Bio. The deal was made on 20-Mar-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Graphite Bio 20-Mar-2024 Merger/Acquisition Biotechnology
To view LENZ Therapeutics’s complete acquisitions history, request access »

LENZ Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.61 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view LENZ Therapeutics’s complete esg history, request access »

LENZ Therapeutics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Lenz Therapeutics Operations Solana Beach, CA 2017

LENZ Therapeutics FAQs

  • When was LENZ Therapeutics founded?

    LENZ Therapeutics was founded in 2013.

  • Where is LENZ Therapeutics headquartered?

    LENZ Therapeutics is headquartered in Solana Beach, CA.

  • What is the size of LENZ Therapeutics?

    LENZ Therapeutics has 152 total employees.

  • What industry is LENZ Therapeutics in?

    LENZ Therapeutics’s primary industry is Drug Discovery.

  • Is LENZ Therapeutics a private or public company?

    LENZ Therapeutics is a Public company.

  • What is LENZ Therapeutics’s stock symbol?

    The ticker symbol for LENZ Therapeutics is LENZ.

  • What is the current stock price of LENZ Therapeutics?

    As of 19-Nov-2026 the stock price of LENZ Therapeutics is $3.33.

  • What is the current market cap of LENZ Therapeutics?

    The current market capitalization of LENZ Therapeutics is $105M.

  • What is LENZ Therapeutics’s current revenue?

    The trailing twelve month revenue for LENZ Therapeutics is $12.4M.

  • Who are LENZ Therapeutics’s competitors?

    Opus Genetics, Kodiak Sciences, Cloudbreak Pharma, ONL Therapeutics, and Foventa Therapeutics are some of the 8 competitors of LENZ Therapeutics.

  • What is LENZ Therapeutics’s annual earnings per share (EPS)?

    LENZ Therapeutics’s EPS for 12 months was -$4.49.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process